BACKGROUND: Attention-deficit/hyperactivity disorder is a psychiatric disorder that starts in childhood. The mechanism of action of methylphenidate, the most common treatment for attention deficit hyperactivity disorder, is unclear. In vitro, the affinity of methylphenidate for the norepinephrine transporter (NET) is higher than that for the dopamine transporter (DAT). The goal of this study was to use positron emission tomography to measure the occupancy of brain norepinephrine transporter by methylphenidate in vivo in humans. METHODS: We used (S,S)-[¹¹C] methylreboxetine ([¹¹C]MRB) to determine the effective dose 50 (ED₅₀) of methylphenidate for NET. In a within-subject design, healthy subjects (n = 11) received oral, single-blind placebo and 2.5, 10, and 40 mg of methylphenidate 75 min before [¹¹C]MRB injection. Dynamic positron emission tomography imaging was performed for 2 hours with the High Resolution Research Tomograph. The multilinear reference tissue model with occipital cortex as the reference region was used to estimate binding potential non-displaceable (BP(ND)) in the thalamus and other NET-rich regions. RESULTS: BP(ND) was reduced by methylphenidate in a dose-dependent manner in thalamus and other NET-rich regions. The global ED₅₀ was estimated to be .14 mg/kg; therefore, the average clinical maintenance dose of methylphenidate (.35-.55 mg/kg) produces 70% to 80% occupancy of NET. CONCLUSIONS: For the first time in humans, we demonstrate that oral methylphenidate significantly occupies NET at clinically relevant doses. The ED₅₀ is lower than that for DAT (.25 mg/kg), suggesting the potential relevance of NET inhibition in the therapeutic effects of methylphenidate in attention-deficit/hyperactivity disorder.
BACKGROUND:Attention-deficit/hyperactivity disorder is a psychiatric disorder that starts in childhood. The mechanism of action of methylphenidate, the most common treatment for attention deficit hyperactivity disorder, is unclear. In vitro, the affinity of methylphenidate for the norepinephrine transporter (NET) is higher than that for the dopamine transporter (DAT). The goal of this study was to use positron emission tomography to measure the occupancy of brain norepinephrine transporter by methylphenidate in vivo in humans. METHODS: We used (S,S)-[¹¹C] methylreboxetine ([¹¹C]MRB) to determine the effective dose 50 (ED₅₀) of methylphenidate for NET. In a within-subject design, healthy subjects (n = 11) received oral, single-blind placebo and 2.5, 10, and 40 mg of methylphenidate 75 min before [¹¹C]MRB injection. Dynamic positron emission tomography imaging was performed for 2 hours with the High Resolution Research Tomograph. The multilinear reference tissue model with occipital cortex as the reference region was used to estimate binding potential non-displaceable (BP(ND)) in the thalamus and other NET-rich regions. RESULTS:BP(ND) was reduced by methylphenidate in a dose-dependent manner in thalamus and other NET-rich regions. The global ED₅₀ was estimated to be .14 mg/kg; therefore, the average clinical maintenance dose of methylphenidate (.35-.55 mg/kg) produces 70% to 80% occupancy of NET. CONCLUSIONS: For the first time in humans, we demonstrate that oral methylphenidate significantly occupies NET at clinically relevant doses. The ED₅₀ is lower than that for DAT (.25 mg/kg), suggesting the potential relevance of NET inhibition in the therapeutic effects of methylphenidate in attention-deficit/hyperactivity disorder.
Authors: Benedetto Vitiello; Howard B Abikoff; Shirley Z Chuang; Scott H Kollins; James T McCracken; Mark A Riddle; James M Swanson; Tim Wigal; James J McGough; Jaswinder K Ghuman; Sharon B Wigal; Anne M Skrobala; Mark Davies; Kelly Posner; Charles Cunningham; Laurence L Greenhill Journal: J Child Adolesc Psychopharmacol Date: 2007-10 Impact factor: 2.576
Authors: Yu-Shin Ding; Tarun Singhal; Beata Planeta-Wilson; Jean-Dominique Gallezot; Nabeel Nabulsi; David Labaree; Jim Ropchan; Shannan Henry; Wendol Williams; Richard E Carson; Alexander Neumeister; Robert T Malison Journal: Synapse Date: 2010-01 Impact factor: 2.562
Authors: Nora D Volkow; Joanna S Fowler; Gene-Jack Wang; Frank Telang; Jean Logan; Christopher Wong; Jim Ma; Kith Pradhan; Helene Benveniste; James M Swanson Journal: PLoS One Date: 2008-04-16 Impact factor: 3.240
Authors: Nora D Volkow; Gene-Jack Wang; Dardo Tomasi; Scott H Kollins; Tim L Wigal; Jeffrey H Newcorn; Frank W Telang; Joanna S Fowler; Jean Logan; Christopher T Wong; James M Swanson Journal: J Neurosci Date: 2012-01-18 Impact factor: 6.167
Authors: Shu-fei Lin; Xiaoning Fan; Catherine Weikart Yeckel; David Weinzimmer; Tim Mulnix; Jean-Dominique Gallezot; Richard E Carson; Robert S Sherwin; Yu-Shin Ding Journal: Nucl Med Biol Date: 2012-05-16 Impact factor: 2.408
Authors: Daniel K Campbell-Meiklejohn; Arndis Simonsen; Mads Jensen; Victoria Wohlert; Trine Gjerløff; Jørgen Scheel-Kruger; Arne Møller; Chris D Frith; Andreas Roepstorff Journal: Neuropsychopharmacology Date: 2012-02-08 Impact factor: 7.853
Authors: Robert H Pietrzak; Jean-Dominique Gallezot; Yu-Shin Ding; Shannan Henry; Marc N Potenza; Steven M Southwick; John H Krystal; Richard E Carson; Alexander Neumeister Journal: JAMA Psychiatry Date: 2013-11 Impact factor: 21.596
Authors: Gislaine Z Réus; Giselli Scaini; Camila B Furlanetto; Meline O S Morais; Isabela C Jeremias; Lis Mairá Mello-Santos; Karolina V Freitas; João Quevedo; Emilio L Streck Journal: Neurotox Res Date: 2013-02-20 Impact factor: 3.911